Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price traded down 9.6% on Monday after the company announced weaker than expected quarterly earnings. The stock traded as low as $5.23 and last traded at $5.16. 9,031,494 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 12,478,559 shares. The stock had previously closed at $5.70.
The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the firm posted ($0.39) EPS. The company's revenue was up 7.2% compared to the same quarter last year.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on RXRX shares. Morgan Stanley dropped their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC lowered their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday. Finally, Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has an average rating of "Hold" and an average price target of $7.60.
View Our Latest Report on Recursion Pharmaceuticals
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of large investors have recently bought and sold shares of RXRX. ARK Investment Management LLC raised its position in shares of Recursion Pharmaceuticals by 7.6% during the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock worth $184,174,000 after purchasing an additional 2,469,104 shares during the period. Vanguard Group Inc. increased its position in Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after buying an additional 9,737,196 shares during the period. Softbank Group CORP. bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at $99,152,000. Kinnevik AB publ boosted its holdings in shares of Recursion Pharmaceuticals by 12.8% during the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock valued at $71,067,000 after acquiring an additional 1,528,503 shares during the period. Finally, Novo Holdings A S bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $68,375,000. Institutional investors own 89.06% of the company's stock.
Recursion Pharmaceuticals Stock Performance
The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -2.83 and a beta of 0.99. The stock's fifty day moving average is $5.57 and its two-hundred day moving average is $6.68. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
